What's New

News

2018/11/28
Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication and Dosage & Administration of Breast Cancer with HER2 Overexpression
2018/09/27
Updated information of CSR
2018/08/20
Nippon Kayaku launches Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK”, a humanized anti-human HER2 monoclonal Antibody
2018/03/23
Nippon Kayaku Receives Manufacture and Marketing Approval in Japan for Biosimilar of Trastuzumab Monoclonal Antibody
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR